US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Redeye and Isofol are inviting to the live broadcast of pre-ASCO on May 28th

In connection to this year's major cancer congress ASCO (American Society of Clinical Oncology ) in Chicago in June, Redeye brings together the seven most interesting cancer companies in the Nordic region for a discussion about the major changes in progress and how the companies position themselves in this fast growing theraputic area worth over $ 100 billion a year.Isofol is presented at 09.40 and will present its clinical activities and the cancer drug candidate, Arfolitixorin, which is primarily intended for the treatment of advanced colorectal cancer. Isofol will

From the ongoing ISO-CC-005 study, Isofol reports initial indications of efficacy of Modufolin® in patients with metastatic colorectal cancer

Isofol Medical AB (publ), a clinical oncology company, announces that the initial indications of Modufolin® efficacy in the ISO-CC-005 study are encouraging and support execution of the planned pivotal efficacy study, ISO-CC-007.To date, 38 patients with mCRC have been treated in the ongoing ISO-CC-005 study. These have received several treatment lines ranging from first to third and even fifth line. The study evaluates different doses of Modufolin® in combination with 5-FU with or without irinotecan, oxaliplatin or bevacizumab.  Isofol's planned pivotal study ISO-CC-007, scheduled to begin

Isofol announces its intention to list on Nasdaq First North Premier

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES.For a complete press release follow the link http://isofol.se/ipo For additional information, please contact:Anders Rabbe, CEO, Isofol, Mob: +46 70 764 65 00, Email: anders.rabbe@isofolmedical.comJan-Eric Österlund, Executive Chairman of the Board, Isofol, Mob: +44 77 853 68 155,

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe